IcoSApent ethyL to slow down aortic VAlve stenosis proGrEssion (SALVAGE)

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517342-33-01

Enrollment

110

Registered

2024-09-26

Start date

Unknown

Completion date

Unknown

Last updated

2024-09-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Aortic valve stenosis

Brief summary

Change in aortic valve calcium (AVC) at 24 months

Detailed description

Change in peak aortic jet velocity at 24 months, Change in calculated aortic valve area (AVA) at 24 months, Total coronary plaque volume progression (mm2), Non-calcified coronary plaque volume progression (mm2)

Interventions

DRUGVazkepa 998 mg soft capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change in aortic valve calcium (AVC) at 24 months	—

Secondary

Measure	Time frame
Change in peak aortic jet velocity at 24 months, Change in calculated aortic valve area (AVA) at 24 months, Total coronary plaque volume progression (mm2), Non-calcified coronary plaque volume progression (mm2)	—

Countries

Netherlands

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026